New Jersey 2022-2023 Regular Session

New Jersey Assembly Bill AJR234 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	ASSEMBLY JOINT RESOLUTION No. 234 STATE OF NEW JERSEY 220th LEGISLATURE INTRODUCED NOVEMBER 30, 2023
2	2
3	3	ASSEMBLY JOINT RESOLUTION
4	4
5	5	No. 234
6	6
7	7
8	8
9	9	STATE OF NEW JERSEY
10	10
11	11	220th LEGISLATURE
12	12
13	13
14	14
15	15	INTRODUCED NOVEMBER 30, 2023
16	16
17	17
18	18
19	19	Sponsored by: Assemblyman HERB CONAWAY, JR. District 7 (Burlington) SYNOPSIS Designates first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ. CURRENT VERSION OF TEXT As introduced.
20	20
21	21
22	22
23	23	Sponsored by:
24	24
25	25	Assemblyman HERB CONAWAY, JR.
26	26
27	27	District 7 (Burlington)
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37	SYNOPSIS
38	38
39	39	Designates first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ.
40	40
41	41
42	42
43	43	CURRENT VERSION OF TEXT
44	44
45	45	As introduced.
46	46
47	47
48	48
49	49	A Joint Resolution designating "Tardive Dyskinesia Awareness Week." Whereas, Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts; and Whereas, TD is an involuntary movement disorder caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression; and Whereas, Clinical research by the United States Food and Drug Administration has led to the availability of two treatments for adults with TD; and Whereas, Many people with serious mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs); and Whereas, While prolonged treatment with these medications are often necessary to treat various illnesses that a person is experiencing, ongoing use of DRBAs can lead to the onset of TD; and Whereas, It is important that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association; and Whereas, It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed; and Whereas, TD is treatable if a patient receives timely screening and diagnosis; and Whereas, However, TD remains widely unknown and misunderstood due to a lack of public awareness and limited resources available to patients, providers, and caregivers; and Whereas, It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment which can lead to the onset of TD; and Whereas, Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment; and Whereas, People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society; and Whereas, To help ensure that people living with TD receive the care they need increased awareness is necessary at the State and federal level; and Whereas, A Tardive Dyskinesia Awareness Week would provide New Jerseyans with an annual reminder to check themselves for symptoms of the disorder and seek early medical intervention through annual screenings with their medical provider; now, therefore, Be It Resolved by the Senate and General Assembly of the State of New Jersey: 1. The first full week of May of each year is designated as "Tardive Dyskinesia Awareness Week" in NJ to encourage New Jerseyans to take preventative steps to identify the symptoms and risk factors of Tardive Dyskinesia. 2. The Governor is respectfully requested to annually issue a proclamation recognizing the first full week of May as "Tardive Dyskinesia Awareness Week" in New Jersey. 3. This joint resolution shall take effect immediately. STATEMENT This resolution designates the first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ. Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts. This involuntary movement disorder is caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression. People with mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs). It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment, which can lead to the onset of TD. It is vital that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association because long-term use of DRBAs can lead to the onset of TD. People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements, which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society. It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed. Although TD is treatable, many people with the disorder are unaware of the treatment options. Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment.
50	50
51	51	A Joint Resolution designating "Tardive Dyskinesia Awareness Week."
52	52
53	53
54	54
55	55	Whereas, Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts; and
56	56
57	57	Whereas, TD is an involuntary movement disorder caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression; and
58	58
59	59	Whereas, Clinical research by the United States Food and Drug Administration has led to the availability of two treatments for adults with TD; and
60	60
61	61	Whereas, Many people with serious mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs); and
62	62
63	63	Whereas, While prolonged treatment with these medications are often necessary to treat various illnesses that a person is experiencing, ongoing use of DRBAs can lead to the onset of TD; and
64	64
65	65	Whereas, It is important that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association; and
66	66
67	67	Whereas, It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed; and
68	68
69	69	Whereas, TD is treatable if a patient receives timely screening and diagnosis; and
70	70
71	71	Whereas, However, TD remains widely unknown and misunderstood due to a lack of public awareness and limited resources available to patients, providers, and caregivers; and
72	72
73	73	Whereas, It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment which can lead to the onset of TD; and
74	74
75	75	Whereas, Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment; and
76	76
77	77	Whereas, People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society; and
78	78
79	79	Whereas, To help ensure that people living with TD receive the care they need increased awareness is necessary at the State and federal level; and
80	80
81	81	Whereas, A Tardive Dyskinesia Awareness Week would provide New Jerseyans with an annual reminder to check themselves for symptoms of the disorder and seek early medical intervention through annual screenings with their medical provider; now, therefore,
82	82
83	83
84	84
85	85	Be It Resolved by the Senate and General Assembly of the State of New Jersey:
86	86
87	87
88	88
89	89	1. The first full week of May of each year is designated as "Tardive Dyskinesia Awareness Week" in NJ to encourage New Jerseyans to take preventative steps to identify the symptoms and risk factors of Tardive Dyskinesia.
90	90
91	91
92	92
93	93	2. The Governor is respectfully requested to annually issue a proclamation recognizing the first full week of May as "Tardive Dyskinesia Awareness Week" in New Jersey.
94	94
95	95
96	96
97	97	3. This joint resolution shall take effect immediately.
98	98
99	99
100	100
101	101
102	102
103	103	STATEMENT
104	104
105	105
106	106
107	107	This resolution designates the first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ. Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts. This involuntary movement disorder is caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression. People with mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs). It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment, which can lead to the onset of TD.
108	108
109	109	It is vital that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association because long-term use of DRBAs can lead to the onset of TD. People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements, which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society. It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed. Although TD is treatable, many people with the disorder are unaware of the treatment options. Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment.